Article
Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis.
Neurobiology of aging - 1 Mar 2015
Lu Hai-Peng, Gan Shi-Rui, Chen Sheng, Li Hong-Fu, Liu Zhi-Jun, Ni Wang, Wang Ning, Wu Zhi-Ying
Abstract excerpt
An effective treatment for amyotrophic lateral sclerosis (ALS) has not yet been found because the pathogenesis of this fatal disease is not well understood. A number of previous studies demonstrated that intermediate-length polyglutamine repeats within the ataxin-2 gene (ATXN2) might be a risk factor among patients with ALS in Western countries. Here, we aim to determine whether this sequence is a risk factor in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
